Demographic data
|
Median age (years)
|
66 (range: 14–91)
|
71.5 (range: 50–78)
|
65 (range: 14–91)
|
0.43
|
Male gender
|
254 (67.9%)
|
4 (50.0%)
|
241 (69.9%)
|
0.23
|
Median duration of stay (days)
|
3 (range: 1–45)
|
14 (range: 7–30)
|
3 (range: 1–45)
|
0.01
|
Underlying disease/treatment
|
Haemato-oncological disease
|
62 (16.6%)
|
1 (12.5%)
|
58 (16.8%)
|
0.74
|
Immunosuppressive disease
|
71 (19.0%)
|
1 (12.5%)
|
66 (19.1%)
|
0.63
|
Hepatic insufficiency
|
17 (4.5%)
|
0 (0%)
|
15 (4.3%)
|
0.55
|
Liver transplantation
|
8 (2.1%)
|
0 (0%)
|
8 (2.3%)
|
0.66
|
Renal insufficiency
|
51 (13.6%)
|
2 (25.0%)
|
41 (11.9%)
|
0.26
|
Long-term dialysis
|
10 (2.7%)
|
1 (12.5%)
|
7 (2.0%)
|
0.05
|
Systemic glucocorticoid treatment
|
36 (9.6%)
|
1 (12.5%)
|
32 (9.2%)
|
0.76
|
Antibiotic treatment
|
218 (58.3%)
|
7 (87.5%)
|
207 (60.0%)
|
0.11
|
Ampicillin
|
7 (3.2%)
|
0 (0%)
|
4 (1.9%)
|
0.76
|
Amoxicillin
|
14 (6.4%)
|
0 (0%)
|
13 (6.3%)
|
0.58
|
Flucloxacillin
|
20 (9.2%)
|
2 (28.6%)
|
15 (7.2%)
|
0.01
|
Piperacillin/tazobactam
|
62 (28.4%)
|
4 (57.1%)
|
55 (26.6%)
|
0.01
|
Cefuroxime
|
130 (59.6%)
|
1 (14.2%)
|
127 (61.4%)
|
0.16
|
Ceftriaxone
|
7 (3.2%)
|
0 (0%)
|
3 (1.4%)
|
0.79
|
Meropenem
|
41 (18.8%)
|
2 (28.6%)
|
36 (17.4%)
|
0.19
|
Clindamycin
|
7 (3.2%)
|
0 (0%)
|
7 (3.4%)
|
0.68
|
Daptomycin
|
8 (3.7%)
|
0 (0%)
|
5 (2.4%)
|
0.73
|
Linezolid
|
3 (1.4%)
|
0 (0%)
|
3 (1.4%)
|
0.79
|
Rifampicin
|
13 (6.0%)
|
0 (0%)
|
10 (4.8%)
|
0.63
|
Erythromycin
|
7 (3.2%)
|
0 (0%)
|
6 (2.9%)
|
0.71
|
Vancomycin
|
19 (8.7%)
|
0 (0%)
|
16 (7.7%)
|
0.53
|
Fosfomycin
|
7 (3.2%)
|
0 (0%)
|
6 (2.9%)
|
0.71
|
Trimethoprim/Sulfamethoxazole
|
6 (2.8%)
|
0 (0%)
|
6 (2.9%)
|
0.71
|
Metronidazole
|
8 (3.7%)
|
0 (0%)
|
7 (3.4%)
|
0.68
|
Previous contact to healthcare system
|
Admission from a foreign hospital
|
1 (0.3%)
|
0 (0%)
|
1 (0.3%)
|
0.88
|
Admission from a domestic hospital
|
188 (50.2%)
|
5 (62.5%)
|
173 (50.0%)
|
0.49
|
Admission from an intensive care unit
|
90 (24.1%)
|
4 (50.0%)
|
76 (22.0%)
|
0.06
|